Genetic-Dependent Cardiovascular Response to PPAR-Alpha Agonist Fenofibrate
Conditions: Type 2 Diabetes; Cardiovascular Diseases; Pharmacogenomic Drug Interaction Interventions: Drug: Fenofibrate 145 mg; Drug: Placebo Sponsor: Mario Luca Morieri Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cardiology | Cardiovascular | Diabetes | Endocrinology | Fenofibrate | Genetics | Heart | Research | Tricor